More reading....
Synthetic Blood International Inc.
Announces New Chief Financial
Officer
August 25, 1998
KETTERING, Ohio--(BUSINESS WIRE) via NewsEdge Corporation --
Synthetic Blood International Inc. (OTCBB:SYBD) announced today that it
has appointed David H. Johnson as chief financial officer.
He will direct the company's institutional investor program in addition to
managing all financial matters for the biomedical product development
company. Johnson is a former partner and regional coordinator of audit and
accounting services with McGladrey & Pullen, a major public accounting firm.
Johnson has over 25 years of financial and administrative experience in a
diverse range of industries including high technology. His prior financial
management experience includes top management positions in finance and
administration, and 18 years in public accounting with McGladrey & Pullen.
He has a B.A. in accounting and is a certified public accountant.
"We are pleased to have a person with Dave Johnson's strong finance and
management background assume this important position as we seek a new
round of funding," said Robert Nicora, president of SYBD. "Because of his
public accounting firm experience, Dave is uniquely qualified to coordinate
and focus the Company's efforts to attract institutional investors."
SYBD is developing Oxycyte(TM), a perfluorocarbon blood substitute
emulsion; Fluorovent(TM), a perfluorocarbon liquid ventilation product; and
an implanted biosensor for continuous monitoring of blood glucose levels in
diabetics.
SYBD is located in Kettering, Ohio, and has West Coast offices and
laboratory facilities in Irvine, Calif. The company's stock is traded on the
OTC Electronic Bulletin Board, symbol SYBD.
CONTACT: Synthetic Blood International, Inc. | Joan Mahan,
800/809-6054
[Copyright 1998, Business Wire] |
